Advanced Treatment for Non-Small Cell Lung Cancer (NSCLC)

Molecular Name: Sotorasib

Active Ingredient: Sotorasib

Strength: Sotorasib is available in different strengths, including 120 mg and 320mg also 240 tablets per box pack size.

Manufacturer Name:

List of Excipients:
Tablet core:
1.Lactose monohydrate 2.Microcrystalline cellulose
3.Croscarmellose sodium
4.Magnesium stearate
1.Polyvinyl alcohol
2.Titanium dioxide (E171)
3.Macrogol 3350

Sotorasib is a cutting-edge medication specifically designed to treat a prevalent form of lung cancer known as non-small cell lung cancer (NSCLC). With its innovative approach and targeted action, Sotorasib offers renewed hope to patients and their families by addressing the complexities of NSCLC.

Special Storage Precautions: Sotorasib tablets should be stored at controlled room temperature between 20°C and 25°C (68°F to 77°F). The tablets should be protected from light and moisture. It’s important to follow the storage instructions provided by the manufacturer and your healthcare provider.

Key Features:
Targeted Treatment: Sotorasib is designed to specifically target NSCLC cells, minimizing damage to healthy cells.
Personalized Approach: Tailored treatment plans based on individual patient profiles and genetic markers.
Clinical Effectiveness: Proven efficacy in combating NSCLC and improving patient outcomes.
Rigorous Testing: Rigorously tested for safety and effectiveness through extensive clinical trials.
Expert Endorsement: Backed by leading oncologists and healthcare professionals in the field.
Form: Oral tablets
Dosage Strengths: Available in various strengths for personalized dosing
Packaging: Securely sealed and labeled packaging

Usage Guidelines:

Sotorasib is intended for adult patients diagnosed with non-small cell lung cancer (NSCLC), particularly those who have shown specific genetic mutations that make them suitable candidates for targeted therapy.


Disclaimer: Sotorasib is a prescription medication. This page does not constitute medical advice and should not be used as a substitute for professional medical consultation. Always consult with a qualified healthcare provider before starting any new treatment.


  1. Sotorasib is not recommended for individuals who have not been diagnosed with NSCLC or do not possess the specific genetic markers associated with the targeted therapy. Pregnant or breastfeeding individuals should also avoid Sotorasib, as its effects on fetal development are not yet fully understood.

Sotorasib should be stored in its original packaging at room temperature, away from direct sunlight and moisture. Keep the medication out of reach of children and pets.

  1. Sotorasib has demonstrated significant effectiveness in treating NSCLC patients with specific genetic mutations. Clinical studies have shown positive outcomes in terms of tumor reduction and disease control.
  1. Sotorasib is administered orally in the form of tablets. The exact dosage and administration schedule will be determined by your healthcare provider based on your individual condition and needs.
  1. Like all medications, Sotorasib may have potential side effects. Common side effects include nausea, diarrhea, fatigue, and changes in liver function. Your healthcare provider will discuss potential side effects and monitoring protocols with you before starting treatment.